Top

Published in:

01-09-2006

Anti-High-Mobility Group Box Chromosomal Protein 1 Antibodies Improve Survival of Rats with Sepsis

Authors: Koichi Suda, MD, Yuko Kitagawa, MD, PhD, Soji Ozawa, MD, PhD, Yoshiro Saikawa, MD, PhD, Masakazu Ueda, MD, PhD, Masahito Ebina, MD, PhD, Shingo Yamada, PhD, Satoru Hashimoto, MD, PhD, Shinji Fukata, MD, PhD, Edward Abraham, MD, Ikuro Maruyama, MD, PhD, Masaki Kitajima, MD, PhD, Akitoshi Ishizaka, MD, PhD

Published in: World Journal of Surgery | Issue 9/2006

Abstract

Background

High-mobility group box chromosomal protein 1 (HMGB1) has recently been shown to be an important late mediator of endotoxin shock, intraabdominal sepsis, and acute lung injury, and a promising therapeutic target of severe sepsis. We sought to investigate the effect of antibodies to HMGB1 on severe sepsis in a rat cecal ligation and puncture (CLP) model.

Methods

Adult male Sprague-Dawley rats underwent CLP and then were randomly divided into two groups: treatment with anti-HMGB1 polyclonal antibodies, and non-immune IgG-treated controls. The serum HMGB1 concentrations were measured at ten time points (preoperatively, and postoperatively at 4, 8, 20, 32, and 48 h and at 3, 4, 5, and 6 days). Hematoxylin-eosin staining, elastica-Masson staining, and immunohistochemical staining for HMGB1 were performed on the cecum and the lung to assess pathological changes 24 h after the CLP procedure.

Results

Treatment with anti-HMGB1 antibodies significantly increased survival [55% (anti-HMGB1) vs. 9% (controls); P< 0.01]. The serum HMGB1 concentrations at postoperative hours 20 and 32 of the anti-HMGB1 antibody-treated animals were significantly lower than those of the controls (P < 0.05). Treatment with anti-HMGB1 antibodies markedly diminished the pathological changes and the number of HMGB1-positive cells in the cecum and the lung.

Conclusions

The present study demonstrates that anti-HMGB1 antibodies are effective in the treatment of severe sepsis in a rat model, thereby supporting the relevance of HMGB1 eradication therapy for severe sepsis.

Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248–251PubMedCrossRef

Abraham E, Arcaroli J, Carmody A, et al. Cutting edge: HMG-1 as a mediator of acute lung inflammation. J Immunol 2000;165:2950–2954PubMed

Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004;255:320–331PubMedCrossRef

Ueno H, Matsuda T, Hashimoto S, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004;170:1310–1316PubMedCrossRef

Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock—a review of laboratory models and a proposal. J Surg Res 1980;29:189–201PubMedCrossRef

Baker CC, Chaudry IH, Gaines HO, et al. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 1983;94:331–335PubMed

Anton EO, Quintela AG, Soto AL, et al. Cecal ligation and puncture as a model of sepsis in the rat: influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor alpha levels. Eur Surg Res 2001;33:77–79CrossRef

Heuer JG, Bailey DL, Sharma GR, et al. Cecal ligation and puncture with total parenteral nutrition: a clinically relevant model of the metabolic, hormonal, and inflammatory dysfunction associated with critical illness. J Surg Res 2004;121:178–186PubMedCrossRef

Andersson U, Tracey KJ. HMGB1 in sepsis. Scand J Infect Dis 2003;35:577–584PubMedCrossRef

10.

Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 2004;255:332–343PubMedCrossRef

11.

Querini PR, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5:825–830CrossRef

12.

Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296–301PubMedCrossRef

13.

Jensenius JC, Andersen I, Hau J, et al. Eggs: conveniently packaged antibodies. Methods for purification of yolk IgG. J Immunol Methods 1981;46:63–68PubMedCrossRef

14.

Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005;115:1267–1274PubMedCrossRef

15.

Yamada S, Inoue K, Yakabe K, et al. High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 2003;49:1535–1537PubMedCrossRef

16.

Naito Z, Ishiwata T, Kurban G, et al. Expression and accumulation of lumican protein in uterine cervical cancer cells at the periphery of cancer nests. Int J Oncol 2002;20:943–948PubMed

17.

Glyn E, Evans V, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ 1999;318:1031–1035

18.

Suda K, Kitagawa Y, Ozawa S, et al. Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery? Dis Esophagus 2006;19:5–9PubMedCrossRef

19.

Ono S, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg 1999;177:78–82PubMedCrossRef

20.

Sato N, Koeda K, Ikeda K, et al. Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg 2002;236:184–190PubMedCrossRef

21.

Sato N, Endo S, Kimura Y, et al. Influence of a Human Protease inhibitor on surgical stress induced immunosuppression. Dig Surg 2002;19:300–305PubMedCrossRef

22.

Watanabe T, Kubota S, Nagaya M, et al. The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J Surg Res 2005;124:59–66PubMedCrossRef

23.

Czura CJ, Yang H, Tracey KJ. High mobility group box-1 as a therapeutic target downstream tumor necrosis factor. J Infect Dis 2003;187:S391–S396PubMedCrossRef

24.

Mitchell BR, Ochani M, Li J, et al. IFN-γ induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003;170:3890–3897PubMed

25.

Yang H, Wang H, Tracey KJ. HMG-1 rediscovered as a cytokine. Shock 2001;15:247–253PubMedCrossRef

Title: Anti-High-Mobility Group Box Chromosomal Protein 1 Antibodies Improve Survival of Rats with Sepsis
Authors: Koichi Suda, MD
Yuko Kitagawa, MD, PhD
Soji Ozawa, MD, PhD
Yoshiro Saikawa, MD, PhD
Masakazu Ueda, MD, PhD
Masahito Ebina, MD, PhD
Shingo Yamada, PhD
Satoru Hashimoto, MD, PhD
Shinji Fukata, MD, PhD
Edward Abraham, MD
Ikuro Maruyama, MD, PhD
Masaki Kitajima, MD, PhD
Akitoshi Ishizaka, MD, PhD
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 9/2006
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-005-0369-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Anti-High-Mobility Group Box Chromosomal Protein 1 Antibodies Improve Survival of Rats with Sepsis

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2006

A 7-year Experience with Thoracoscopic Sympathectomy for Critical Upper Limb Ischemia

Diagnosis and Treatment of Gastric Heterotopic Pancreas

Day Care Laparoscopic Cholecystectomy: A Feasibility Study in a Public Health Service Hospital in a Developing Country

DRD2/DARPP-32 Expression Correlates with Lymph Node Metastasis and Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma

Falciform Ligament in the Management of the Residual Cavity for Liver Hydatidosis: New Surgical Technique

Editor’s Note